In a nutshell This study evaluated the safety and effectiveness of BEB (busulfan, etoposide, bendamustine) chemotherapy for patients with non-Hodgkin’s lymphoma (NHL). This study found that BEB chemotherapy was effective and well-tolerated in these patients. Some background Autologous stem cell transplantation (ASCT) is a standard...
Read More
In a nutshell This study evaluated mental functioning in older survivors of non-Hodgkin lymphoma (NHL). This study concluded that these individuals may have some mental function decline and lower mental function compared to individuals who did not have cancer. Some background Research suggests that cancer treatments have been shown to cause...
Read More
In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...
Read MoreIn a nutshell This study compared the outcomes of patients with lymphoma who had an allogeneic stem cell transplant with different sources of stem cells. This study found that stem cells from a matching donor had better outcomes compared to those from unrelated cord blood. Some background Allogeneic stem cell transplantation is one type of stem cell...
Read More
In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (LT) for recurrent or non-responding non-Hodgkin’s lymphoma (NHL). This study found that LT showed promising effectiveness, with manageable side effects. Some background Patients with NHL often receive strong treatment to kill cancer cells. 60 to 70%...
Read More
In a nutshell This study evaluated the outcomes of treatment with high-dose methotrexate (Trexall) plus chemotherapy for diffuse B-cell lymphoma (DLBCL). This study concluded that this regimen was promising, with manageable side effects for these patients. Some background DLBCL is the most common type of non-Hodgkin’s lymphoma. Initial treatment...
Read More
In a nutshell This study evaluated the safety and effectiveness of bendamustine-EAM (Be-EAM) chemotherapy for patients with mantle cell lymphoma (MCL) before a stem cell transplant. This study found that this regimen improved survival outcomes compared to standard regimens. Some background Stem cell transplants (SCT) remain the standard of care for...
Read More
In a nutshell This study evaluated the safety and effectiveness of two different chemotherapy regimens for patients with indolent (painless) non-Hodgkin’s lymphoma (NHL). This study found that the R-CVP regimen was similarly effective and had fewer side effects compared to R-CHOP for these patients. Some background Chemoimmunotherapy is the...
Read More
In a nutshell This looked at the safety and effectiveness of copanlisib (Aliqopa) for B-cell lymphoma that returned after previous treatment. This study found that long-term copanlisib treatment was safe and effective. Some background Indolent (painless) B-cell lymphoma is a slow-growing blood cancer. B-cell lymphoma that comes back or...
Read More
In a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...
Read More
In a nutshell This study evaluated the effectiveness of allogeneic stem cell transplants (allo-SCT) in elderly patients with non-Hodgkin’s lymphoma (NHL). This study found that allo-SCT has improved survival outcomes for these patients. Some background Allogeneic stem cell transplantation (allo-SCT) can be highly effective for patients with...
Read MoreIn a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells. The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH, the...
Read More
